Orkambi and Melatonin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Orkambi (ivacaftor; lumacaftor) and Melatonin (melatonin). Common drug interactions include infective pulmonary exacerbation of cystic fibrosis among females and infective pulmonary exacerbation of cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Orkambi and Melatonin. It is created by eHealthMe based on reports of 77 people who take the same drugs from the FDA, and is updated regularly.

What is Orkambi?

Orkambi has active ingredients of ivacaftor; lumacaftor. eHealthMe is studying from 9,496 Orkambi users. Check the latest studies of Orkambi.

What is Melatonin?

Melatonin has active ingredients of melatonin. It is often used in insomnia. eHealthMe is studying from 56,213 Melatonin users. Check the latest studies of Melatonin.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

77 people who take Orkambi and Melatonin together, and have interactions are studied.

Orkambi and Melatonin drug interactions.

What are the common drug interactions of Orkambi and Melatonin, by gender? *:

female:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Malaise (a feeling of general discomfort or uneasiness)
Blood chloride increased
Blood glucose increased
Blood urea decreased
Bronchial wall thickening
Drug level increased
Forced expiratory volume decreased (decreased lung expired air volume)
Protein total decreased
Vitamin e decreased

male:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pneumonia
Cough
Rib fracture
Abdominal pain
Back pain
Catheter site pain
Drug screen false positive
Infection
Nasopharyngitis (inflammation of the nasopharynx)

What are the common drug interactions of Orkambi and Melatonin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Ear infection
Hospitalisation
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Streptococcal infection
Influenza
Malaise (a feeling of general discomfort or uneasiness)
Nasopharyngitis (inflammation of the nasopharynx)
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Sinusitis (inflammation of sinus)
Viral rash

10-19:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Blood chloride increased
Blood glucose increased
Blood urea decreased
Bronchial wall thickening
Drug level increased
Forced expiratory volume decreased (decreased lung expired air volume)
Protein total decreased
Vitamin e decreased
White blood cell count decreased

20-29:

Dyspnoea (difficult or laboured respiration)
Pyrexia (fever)
Pulmonary function test decreased
Abdominal pain
Back pain
Nausea (feeling of having an urge to vomit)
Respiratory disorder (respiratory disease)
Vomiting
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
Pancreatic atrophy

30-39:

Cough
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Influenza
Rib fracture

40-49:

n/a

50-59:

Hospitalisation
Pneumonia
Rhinovirus infection

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 70 people, 90.91%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 14 people, 18.18%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 13 people, 16.88%
Rickets (softening of bones): 13 people, 16.88%
Pneumonia: 9 people, 11.69%
Pain: 9 people, 11.69%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 8 people, 10.39%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 7 people, 9.09%
Fever: 7 people, 9.09%
Sinusitis (inflammation of sinus): 7 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Orkambi and Melatonin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously